ClinicalTrials.gg

Program

SAR444336

A development code.

In Sanofi's pipeline, Non-beta IL2 Synthorin. Its studies are mostly in Colitis, Microscopic, led by Sanofi.

Furthest: phase 2, since Sep 3, 20252 company-led studies, 1 open or runningNext primary completion: Apr 8, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi21 open or runningphase 2since Sep 3, 2025May 17, 2023Apr 8, 2027phase 2 · NCT07156175
  • Named in Sanofi’s own pipeline as SAR444336, phase 2, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 17, 2023First study: phase 1 study in Healthy VolunteerFirst studyNCT05876767 · 76 enrolled · Netherlands
  2. Sep 3, 2025Phase 2 study in Colitis, MicroscopicNCT07156175 · 60 enrolled · Belgium, Denmark, France and more

Ahead

  1. Apr 8, 2027Primary completion: phase 2 study in Colitis, MicroscopicNCT07156175

TargetBeta

“Non-beta IL2 Synthorin”the company's pipeline, read by Claude · source

Other programs on IL2

ProgramCompanyFurthest phaseStudies
darleukinrulePhilogenphase 39
daromunrulePhilogenphase 36
Daxokafusp AlfaSanofiphase 22
Anti-PD-1/IL-2 Fusion Protein TEV-56278Teva Pharmaceutical Industriesphase 12
IL-2 Mutein/Fc Fusion Protein HM16390ruleHanmi Pharmaceuticalphase 11
Autologous IL-2-expressing Anti-mesothelin CAR T-cells OPB-101ruleoutpace-bio-incphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07156175Colitis, Microscopic · Belgium, Denmark, France and more2Active, not recruitingApr 8, 202760
NCT05876767Healthy Volunteer · Netherlands1CompletedDec 12, 202376

How it is read

Names in the registry

  • “SAR444336”, 2 entries

Codes read as this program: SAR444336.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.